Search

everythingexperts & clinicslearnfaqsresearchcommunity

for

Search:↓

A 30-year-old male switched from finasteride to a combination of dutasteride, oral minoxidil, and RU58841, achieving significant hair growth without side effects. He plans to add GHK-Cu peptide to his regimen for further improvement.

The conversation discusses a hair loss treatment regimen involving minoxidil, finasteride, RU58841, JXL069, and nizoral shampoo. The user reports seeing new black dots in areas where hair hasn't grown in years, suggesting potential regrowth.

A 19-year-old is experiencing hair thinning despite using finasteride, RU58841, LLLT, saw palmetto, pumpkin seed oil, and a healthy lifestyle for 114 days. They are concerned about the lack of improvement and are hesitant to start minoxidil due to dependency concerns.

The user is undergoing Mesotherapy and Low-Level Laser Therapy for hair loss, with plans for multiple sessions. They are also using oral finasteride, topical minoxidil, dutasteride, and hair fibers.

A 23-year-old male experienced significant hair improvement over 9 months using dutasteride, minoxidil, finasteride, PRP, and red light therapy, with no side effects. He plans to continue treatment for 6 more months before deciding on a hair transplant.

The user has been using finasteride and dutasteride for hair loss but is experiencing low energy and motivation, possibly due to high prolactin levels. Despite treatment, hairline recession continues, and the user is considering the impact of low DHT levels on overall health and energy.

PP405 is a new hair loss treatment advancing quickly in trials, generating excitement and skepticism about its effectiveness and marketing claims. Some see it as a potential alternative to minoxidil and finasteride, but concerns about long-term effects and the need for DHT blockers persist.

Clascoterone's European release is expected in Q4 2026, with FDA approval anticipated by mid-2027. The discussion includes questions about the approval timeline and potential acceleration due to unmet needs.

The user is experiencing increased hair shedding and is concerned about regression despite consistent use of finasteride, minoxidil, and other treatments. The consensus is that this is likely a temporary shedding phase, and adjustments to the dermarolling frequency are suggested.

A 37-year-old is starting topical finasteride for hair loss, with lab results showing normal hormone levels. They plan to avoid further research initially and may share future lab results if significant side effects occur.

A 52-year-old male with Multiple Sclerosis is considering using Finasteride and Testosterone Replacement Therapy (TRT) for hair loss but is advised to lose weight first to avoid side effects. He is currently focusing on diet, weight loss, and using Rogaine and microneedling for hair treatment.

PP405 is a new drug in Phase 2 trials for hair loss, generating cautious optimism among users. Some users are currently using finasteride and experiencing side effects, while others are skeptical about unapproved products being sold.

The conversation discusses using RU58841 with primobolan or masteron to protect hair while on steroids, alongside dutasteride. Users suggest caution with these compounds due to potential hair loss and discuss alternatives like nandrolone and EQ for better hair safety.

JXL082 is not the same as PP405, leading to a halt in sales and a plan to synthesize the real PP405. There is skepticism about the safety and effectiveness of JXL082 and PP405, with concerns about patent issues and the long-term impact on hair growth.

People are discussing the potential of a new hair loss treatment, pp405, and its approval timeline, comparing it to existing treatments like Minoxidil and finasteride. There is skepticism about its effectiveness and concerns about the time it will take for approval and availability, especially in Europe.

The user experienced increased hair shedding after using RU58841 for two months, but found relief from scalp itchiness. Other users shared similar shedding experiences and discussed side effects like joint pain, while also mentioning the use of finasteride and minoxidil.

Hair loss may be linked to the TRPS1 gene and protein, not just DHT. Amplifica's AMP-303 targets mesenchymal stem cells and shows promise in treating hair loss, unlike Pelage's PP405.

The conversation is about finding a source for RU58841 as a substitute for finasteride for hair loss treatment. Suggestions include Amazon and Anageninc.com.

PP405 is a promising new treatment for hair loss that activates dormant stem cells in hair follicles, potentially bypassing the effects of DHT. It is currently in phase 2 trials and could be available between 2027 and 2030, but it is not considered a definitive cure.

The user achieved significant hair regrowth using only dutasteride, noticing results after 8-9 months despite initial shedding. They did not use minoxidil due to inconvenience but still experienced permanent hair growth.

The conversation is about hair loss treatments, specifically Pyrludimide (KX-826) and Breezula (clascoterone), with the user unable to tolerate finasteride and dutasteride. The user plans to use these treatments alongside minoxidil, considering the efficacy and availability of each option.

The conversation discusses an experiment involving hair loss treatments, including the use of Verteporfin, KY19382, dutasteride, oral and topical minoxidil, AHK-Cu, and microneedling. The experiment aims to test the effectiveness of these treatments in promoting hair growth and healing without scarring, with updates planned every few months.

The conversation discusses concerns about RU58841 degrading when exposed to light and transferring pyri to a dark glass bottle to prevent this. The user keeps the pyri out for only two minutes before storing it in a dark place.

Kintor Pharmaceutical's stock rise suggests potential positive news about Pyrilutamide, a topical anti-androgen. GT20029 may also compete with existing treatments like finasteride and dutasteride.

A user was prescribed a topical treatment for hair loss including Latanoprost, Minoxidil, Dutasteride, Hydrocortisone, and Progesterone, after using an oral Minoxidil and Finasteride combo without significant results. Concerns were raised about the long-term use of hydrocortisone, with suggestions to consult a doctor regularly.

The conversation discusses hair loss treatments, specifically PRP, Minoxidil, and Finasteride. The user is considering PRP but is concerned about its effectiveness and potential side effects, while another user suggests starting with Minoxidil and possibly adding Finasteride later.

Finasteride prescriptions in France now require an annual certificate acknowledging psychiatric and sexual risks, as the European Medicines Agency recognizes these risks. The conversation discusses the potential mental health effects of Finasteride, with some users reporting side effects and others questioning the statistical significance of these findings.

A user shared their baseline bloodwork results before starting Finasteride 1mg every other day, seeking comparison with others who have done similar tests. They are interested in any changes observed after beginning the treatment.

Extended-release oral minoxidil (VDPHL01) shows promising results for hair growth with improved safety, achieving significant hair count increases and minimal side effects compared to placebo. The treatment is designed to maintain effective concentrations while reducing side effects, making it a safer option for those who cannot tolerate standard minoxidil.

The conversation is about a product called FLEAVA, found in a Facebook ad, and whether it is effective or just another scam. One user believes it is likely a scam and mentions that such products usually don't compete with Minoxidil.